Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 985

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 10
Chunk 985
---
. Except for the foregoing, the terms of such Working Capital
Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either
be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such
Working Capital Loans may be convertible into units of the post-Business Combination entity at a price of $10.00 per unit. The units would
be identical to the Private Placement Units. As of December 31, 2024, no working capital loans were outstanding.

Amended and Restated Private Units Purchase
Agreement and Subscription Promissory Note

Simultaneously with the closing of the Initial Public Offering , the
Company has entered into an amended and restated private units purchase agreement with the Sponsor, pursuant to which the Sponsor agreed
to purchase an aggregate of 400,000 Private Placement Units (or 430,000 Private Placement Units if the underwriters’ over-allotment
is exercised in full) at a price of $10.00 per Private Placement Unit ($4,000,000, or an aggregate of $4,300,000 if the underwriters’
over-allotment is exercised in full) from the Company in the Private Placement. Under the agreement, the Sponsor agreed to provide the
Company up to $1,100,000 in working capital loans under the Subscription Promissory Note, which loans shall be converted into Private
Placement Units, at the price of $10.00 per unit. To the extent the amount of such loans is less than $1,100,000, the Sponsor agreed that
it (or, if applicable, it and any transferees of Private Placement Units) shall surrender for cancellation any and all rights to up to
an aggregate of 110,000 Private Placement Units at $10.00 per unit.

NOTE 6 — COMMITMENTS AND CONTINGENCIES

Risks and Uncertainties

The United States and global markets are
experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and  the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization
(“NATO”) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European
Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus